{Reference Type}: Journal Article
{Title}: Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel.
{Author}: Parsons MT;de la Hoya M;Richardson ME;Tudini E;Anderson M;Berkofsky-Fessler W;Caputo SM;Chan RC;Cline MS;Feng BJ;Fortuno C;Gomez-Garcia E;Hadler J;Hiraki S;Holdren M;Houdayer C;Hruska K;James P;Karam R;Leong HS;Martins A;Mensenkamp AR;Monteiro AN;Nathan V;O'Connor R;Pedersen IS;Pesaran T;Radice P;Schmidt G;Southey M;Tavtigian S;Thompson BA;Toland AE;Turnbull C;Vogel MJ;Weyandt J;Wiggins GAR;Zec L;Couch FJ;Walker LC;Vreeswijk MPG;Goldgar DE;Spurdle AB;
{Journal}: Am J Hum Genet
{Volume}: 111
{Issue}: 9
{Year}: 2024 Sep 5
{Factor}: 11.043
{DOI}: 10.1016/j.ajhg.2024.07.013
{Abstract}: The ENIGMA research consortium develops and applies methods to determine clinical significance of variants in hereditary breast and ovarian cancer genes. An ENIGMA BRCA1/2 classification sub-group, formed in 2015 as a ClinGen external expert panel, evolved into a ClinGen internal Variant Curation Expert Panel (VCEP) to align with Food and Drug Administration recognized processes for ClinVar contributions. The VCEP reviewed American College of Medical Genetics and Genomics/Association of Molecular Pathology (ACMG/AMP) classification criteria for relevance to interpreting BRCA1 and BRCA2 variants. Statistical methods were used to calibrate evidence strength for different data types. Pilot specifications were tested on 40 variants and documentation revised for clarity and ease of use. The original criterion descriptions for 13 evidence codes were considered non-applicable or overlapping with other criteria. Scenario of use was extended or re-purposed for eight codes. Extensive analysis and/or data review informed specification descriptions and weights for all codes. Specifications were applied to pilot variants with pre-existing ClinVar classification as follows: 13 uncertain significance or conflicting, 14 pathogenic and/or likely pathogenic, and 13 benign and/or likely benign. Review resolved classification for 11/13 uncertain significance or conflicting variants and retained or improved confidence in classification for the remaining variants. Alignment of pre-existing ENIGMA research classification processes with ACMG/AMP classification guidelines highlighted several gaps in the research processes and the baseline ACMG/AMP criteria. Calibration of evidence strength was key to justify utility and strength of different data types for gene-specific application. The gene-specific criteria demonstrated value for improving ACMG/AMP-aligned classification of BRCA1 and BRCA2 variants.